A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy

A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy

Stefano Luminari,1,2 Antonio Pinto,3 Benedetta Puccini,4 Alessandro D’Arpino,5 Emanuela Omodeo Salè,6 Marco Bellone,7,* Lorenzo Pradelli,7 Alice Sabinot7,* 1Hematology, Azienda USL IRCCS of Reggio Emilia, Reggio Emilia, Italy; 2CHIMOMO Department, University of Modena and Reggio Emil...

Full description

Saved in:
Bibliographic Details
Main Authors: Luminari S, Pinto A, Puccini B, D’Arpino A, Omodeo Salè E, Bellone M, Pradelli L, Sabinot A
Format: Article
Language:English
Published: Dove Medical Press 2025-04-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
economic evaluation
oncology
social cost
hospital cost
Online Access:https://www.dovepress.com/a-cost-effectiveness-analysis-of-mosunetuzumab-vs-tisagenlecleucel-for-peer-reviewed-fulltext-article-CEOR
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/a-cost-effectiveness-analysis-of-mosunetuzumab-vs-tisagenlecleucel-for-peer-reviewed-fulltext-article-CEOR

Similar Items